Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Bio-electrical Impedance Analysis in Patients With Functional Dyspepsia

NCT07196735 · tracked via the Priya Life Science Belgium tracker
Phase
Observational
Started
2025-09-18
Last updated
2025-10-03

Condition(s) studied

Functional DyspepsiaBIAFat Free MassFat MassPhase Angle

Study summary

The primary objective of this study is to compare the BIA parameters, including Phase Angle, Fat Free Mass and Fat Mass, between women with functional dyspepsia and healthy women. All woman will undergo a bio-electrical impedance monitoring for this.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Women aged 18 - 75 years * Fulfilling the ROME IV criteria for functional dyspepsia (for FD patients) * FD unexplained by upper GI endoscopy during the past 12 months (mild gastritis allowed) (for FD patients). Exclusion Criteria: * Clinical suspicion of an organic disorder different from FD (patients can be included when this disorder had been excluded); * Abnormality on upper GI endoscopy other than mild gastritis (for FD patients). * Known reflux oesophagitis Los Angeles grade C or D, known Barrett oesophagus, peptic stricture. * H pylori infection, unless treated at least 6 months before; * Known inflammatory bowel disorder; * Known major intestinal motility disorder; * Alcohol (defined as more than 14 U per week) or other substance abuse; * Active psychiatric disorder; * Known systemic or auto-immune disorder with implication for the GI system; * Prior abdominal surgery (with the exception of cholecystectomy or ap-pendectomy); * Any prior diagnosis of cancer other than basocellular carcinoma; * Current chemotherapy; * History of gastro-enteritis in the past 12 weeks; * Dietary supplements unless taken at a stable dose for more than 12 weeks; * Treatment with neuromodulators (one neuromodulator taken at a sta-ble dose for more than 12 weeks is allowed); * Treatment with PPI's during the past 8 weeks * Pregnancy.

Primary outcome measure(s)

  • Difference in phase angle between healthy patients and patients with FD — from signing of the ICF till end of study (on average 1 week)
  • Difference in fat mass between healthy patients and patients with FD — from signing of the ICF till end of study (on average 1 week)
  • Difference in fat free mass between healthy patients and patients with FD — from signing of the ICF till end of study (on average 1 week)

Trial sites (1)

FacilityCityRegionStatus
UZ Brussel Brussels Belgium Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07196735 on ClinicalTrials.gov ↗ ← All trials in Belgium